NASDAQ:SONM
DNA X, Inc.
DNA X, Inc. reported net income of −$20.7M in fiscal 2025. The diluted share count rose 175.7%.Summary generated from DNA X, Inc.'s SEC filings. Latest annual report filed Apr 15, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+175.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 55 | 70 | 94 | 58 | n/a |
| Operating income | −38 | −14 | 1 | −3 | −5 |
| Net income | −39 | −14 | −0 | −34 | −21 |
| Free cash flow | −39 | −12 | −4 | −9 | n/a |
Recent filings
- 8-KOther events
Aug 31, 2026 - 8-KDirector or officer change
Aug 27, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 19, 2026 - 8-K/AAmended other events
Aug 13, 2026 - 8-K/AAmended amendment to articles or bylaws
Jul 9, 2026 - 8-KEntry into a material agreement
Jul 2, 2026 - 8-KTermination of a material agreement
Jun 4, 2026 - 8-KEntry into a material agreement
May 27, 2026